Published by: Aaron Brown, Sr. Manager, Market Intelligence Insights Since the FDA and NIH signaled their pivot toward New Approach Methodologies (NAMs) early last year, the most meaningful developments have been in how quickly those signals have turned into practical pathways. FDA’s 2025 roadmap began allowing NAM‑supported INDs—initially for monoclonal antibodies—with options for streamlined review where […]
